Pebmond Associates Ltd
Pebmond Associates provides multifaceted board-level advisory, business development and licensing services. Operating in the EU, US and emerging markets we add value to clients by providing solutions for developing and growing pharma companies, including services from a network of trusted partner companies.
PHASTAR work with small and large pharmaceutical and biotechnology companies to provide statistical consulting and to summarise, analyse and report clinical trials. Our top priority is the quality of our work, ensuring we give you the best statistical advice, and analyse your clinical data optimally, getting it right first time. There are lots of different ways to analyse a set of data. We can advise on how to get the most out of your data. Statistics is an art!
We can work with our own internal systems and processes or seamlessly incorporate with your teams. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.
Our vision is to become the supplier of choice for statistics to the pharma and biotech sector, by delivering quality advice and results, on time and on budget.
Edward ClarkSales and Marketing Director
Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infections with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation. A recent in vivo study demonstrates that Neumonco™ significantly inhibits tumour growth in an orthotopic mouse xenograft model of human ovarian cancer.
Founded in 2016, the Company is a spin-out start-up from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.